ArticlePDF Available

An unusual cause of hypoxia: Getting to the heart of the matter

Authors:

Abstract and Figures

A 63 year old female presented to hospital with progressive exertional dyspnoea over a 6 month period. In the year preceding her admission, she reported an intercurrent history of abdominal pain, diarrhoea and weight loss. She was found to be hypoxic, the cause for which was initially unclear. A ventilation-perfusion scan identified a right-to-left shunt. Transoesophageal echocardiography (TOE) demonstrated a significant right-to-left intracardiac shunt through a patent foramen ovale (PFO); additionally severe tricuspid regurgitation was noted through a highly abnormal tricuspid valve. The findings were consistent with carcinoid heart disease with a haemodynamically significant shunt, resulting in profound systemic hypoxia. 24 hour urinary 5-Hydroxyindoleacetic acid (5-HIAA) and imaging were consistent with a terminal ileal primary carcinoid cancer with hepatic metastasis. Liver biopsy confirmed a tissue diagnosis. The patient was commenced on medical therapy for carcinoid syndrome. She subsequently passed away while undergoing anaesthetic induction for valvular surgery to treat her carcinoid heart disease and PFO.
Content may be subject to copyright.
D Hammersley, A Shamsi
etal.
An unusual cause of hypoxia K7–K11
5:1
CASE REPORT
An unusual cause of hypoxia: getting to the
heart of the matter
DanielHammersley1,*, AamirShamsi2,*, MohammadMurtazaZaman3, Philip Berry4 and LydiaSturridge1
1Frimley Park Hospital, Frimley, Surrey, UK
2St George’s Hospital, London, UK
3Royal Brompton Hospital, London, UK
4Guy's & St Thomas’ NHS Foundation Trust, London, UK
*(D Hammersley and A Shamsi contributed equally to this work)
Correspondence should be addressed to D Hammersley: djhammersley@gmail.com
Summary
A 63-year-old female presented to hospital with progressive exertional dyspnoea over
a 6-month period. In the year preceding her admission, she reported an intercurrent
history of abdominal pain, diarrhoea and weight loss. She was found to be hypoxic, the
cause for which was initially unclear. A ventilation–perfusion scan identied a right-to-
left shunt. Transoesophageal echocardiography (TOE) demonstrated a signicant right-
to-left intracardiac shunt through a patent foramen ovale (PFO); additionally severe
tricuspid regurgitation was noted through a highly abnormal tricuspid valve. The ndings
were consistent with carcinoid heart disease with a haemodynamically signicant shunt,
resulting in profound systemic hypoxia. 24-h urinary 5-hydroxyindoleacetic acid (5-HIAA)
and imaging were consistent with a terminal ileal primary carcinoid cancer with hepatic
metastasis. Liver biopsy conrmed a tissue diagnosis. The patient was commenced on
medical therapy for carcinoid syndrome. She subsequently passed away while undergoing
anaesthetic induction for valvular surgery to treat her carcinoid heart disease and PFO.
Learning points:
Carcinoid syndrome is a rare condition, which presents a signicant diagnostic challenge due to its insidious
presentation and symptoms. This frequently results in a marked delay in diagnosis.
Carcinoid heart disease is characterised by distortion and xation of right-sided heart valves, which cause valvular
regurgitation, stenosis or both. Valvular abnormalities are often found in association with right ventricular failure.
In the case described, carcinoid heart disease was found in association with a signicant right-to-left intracardiac
shunt, created through a PFO due to right atrial volume overload. This prevented right ventricular failure at the
expense of creating a state of severe induced systemic hypoxia.
This physiological adaptation resulted in an unusual presentation of this condition, due to symptoms resulting
from hypoxia, rather than the classical symptoms of carcinoid syndrome or right ventricular failure.
Key Words
fcarcinoid syndrome
fpatent foramen ovale
fshunt
10.1530/ERP-17-0055
ID: 17-0044
51
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International License.
https://doi.org/10.1530/ERP-17-0055
www.echorespract.com © 2018 The authors
Published by Bioscientica Ltd
D Hammersley, A Shamsi
etal.
An unusual cause of hypoxia K8
5:1
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International License.
https://doi.org/10.1530/ERP-17-0055
www.echorespract.com © 2018 The authors
Published by Bioscientica Ltd
Background
Exertional breathlessness is a common presenting
complaint in acute medicine. Hypoxia is a common
clinical finding in these patients. This case demonstrates
an unusual cause of hypoxia. Standard first-line
investigations would not have reached the underlying
diagnosis in this case and as such it demonstrates the
complex investigative strategy required to reach this
diagnosis. The case illustrates the challenges of diagnosing
carcinoid syndrome. It was only through investigation
of the exertional breathlessness that the underlying
diagnosis of carcinoid syndrome with carcinoid heart
disease was made.
Case presentation
A 63-year-old female presented acutely to hospital with
progressive dyspnoea over the previous 6 months. She
had no other significant medical co-morbidities, but
2 months previously had been investigated for chronic
lower abdominal pain, weight loss and diarrhoea,
which had started 1year beforehand. Recent outpatient
investigations into her gastrointestinal symptoms,
including a pelvic ultrasound scan and a colonoscopy, had
been unremarkable and consequently these symptoms
had been attributed to irritable bowel syndrome.
On admission to hospital, she was cachectic with a
body mass index (BMI) of 19. Observations identified
resting hypoxia, with oxygen saturation of 91% on room
air; other observations were within normal parameters.
Cardiovascular examination revealed a pansystolic
murmur at the left sternal edge, there was no peripheral
oedema and her venous jugular pressure was not elevated.
Respiratory system examination was unremarkable with
no peripheral or central cyanosis and vesicular breath
sounds bilaterally throughout the lung fields.
Investigation
Arterial blood gas on room air confirmed type I respiratory
failure with pO2 7.64 kPa. Blood tests (including full blood
count, renal function, liver function and C-reactive
protein) were all unremarkable. 12-lead electrocardiogram
showed normal sinus rhythm with a normal cardiac axis.
Chest radiograph was unremarkable and did not identify
any parenchymal, interstitial or pleural abnormalities
that could account for the hypoxia.
A computed tomography (CT) pulmonary angio-
gram demonstrated no evidence of a pulmonary
embolism, but an ill-defined hypodense lesion in the
liver was noted that was suspicious for a metastatic
deposit. Persistent hypoxia was further investigated
with a ventilation–perfusion (VQ) nuclear scan, which
showed no evidence of perfusion defect to suggest
thromboembolic disease, but did confirm the presence
of a large right-to-left shunt.
Echocardiography was performed to assess for
the presence of an intracardiac shunt. Transthoracic
echocardiography (TTE) was limited by suboptimal
windows, but identified an abnormal tricuspid valve
appearance with restriction and splinting of the valve
leaflets with loss of coaptation causing severe regurgitation
and mild stenosis (Figs1, 2 and Video1). Right ventricular
Figure1
TTE apical 4-chamber view, demonstrating abnormal tricuspid valve
appearance.
Figure2
Colour Doppler showing severe tricuspid regurgitation.
D Hammersley, A Shamsi
etal.
An unusual cause of hypoxia K9
5:1
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International License.
https://doi.org/10.1530/ERP-17-0055
www.echorespract.com © 2018 The authors
Published by Bioscientica Ltd
dimensions (Fig. 3) and systolic function were within
normal limits (Fig.4).
Transoesophageal echocardiography (TOE)
demonstrated a highly mobile aneurysmal ‘skipping rope’
interatrial septum (Video 2). Colour Doppler confirmed
flow across the interatrial septum (Fig. 5). Bubble saline
contrast injection identified a significant right-to-left
shunt through a PFO (Videos3 and 4). Aortic and mitral
valves were mildly thickened and only mildly regurgitant.
The mechanism of the shunt was therefore identified
as an acquired intracardiac circuit occurring as a result
of a severely regurgitant tricuspid valve with the jet of
regurgitation being directed across a PFO into the left
atrium due to right atrial volume overload.
In view of the patient’s symptoms of weight loss,
abdominal pain and diarrhoea, 24-h urinary collection
for 5-hydroxyindoleacetic acid (5-HIAA) was performed.
This was significantly elevated at 717 μmol/24 h (normal
range <42 μmol/24 h) and therefore strongly suggestive
of carcinoid syndrome as the underlying pathology.
Serum chromogranin A and B levels were elevated. ACT
abdomen and pelvis identified a 1 cm hypervascular
lesion in the terminal ileum in addition to mesenteric
lymphadenopathy and a hypervascular hepatic lesion,
in keeping with a primary carcinoid lesion with hepatic
metastasis. MRI liver confirmed an 8 cm right liver lobe
Figure3
TTE apical 4-chamber view demonstrating normal right ventricular
dimensions.
Figure4
M-mode demonstrating normal RV systolic function, as indicated by
TAPSE 2.1 cm.
Figure5
TOE mid-oesophageal aortic valve short axis view with colour Doppler,
demonstrating signicant ow across the interatrial septum.
Video 4
TOE bubble saline contrast injection demonstrating
signicant right-to-left shunt. View Video 4 at http://
movie-usa.glencoesoftware.com/video/10.1530/ERP-17-
0055/video-4.
Video 1
TTE apical 4-chamber view, demonstrating restriction and
splinting of the tricuspid valve leaets. View Video 1 at
http://movie-usa.glencoesoftware.com/video/10.1530/
ERP-17-0055/video-1.
Video 2
TOE mid-oesophageal aortic valve short axis view,
demonstrating highly mobile aneurysmal ‘skipping rope’
interatrial septum. View Video 2 at http://movie-usa.
glencoesoftware.com/video/10.1530/ERP-17-0055/video-2.
Video 3
TTE bubble saline contrast injection demonstrating
signicant right-to-left shunt. View Video 3 at http://
movie-usa.glencoesoftware.com/video/10.1530/ERP-17-
0055/video-3.
D Hammersley, A Shamsi
etal.
An unusual cause of hypoxia K10
5:1
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International License.
https://doi.org/10.1530/ERP-17-0055
www.echorespract.com © 2018 The authors
Published by Bioscientica Ltd
mass. Octreotide scan confirmed a solitary hepatic deposit
with further uptake in the terminal ileum. Percutaneous
biopsy of the liver lesion confirmed a well-differentiated
metastatic carcinoid tumour.
Treatment and outcome
Sandostatin, an analogue of the hypothalamic release-
inhibiting hormone somatostatin, was commenced which
resulted in temporary relief of gastrointestinal symptoms.
The patient’s care was transferred to a tertiary centre
experienced in the management of carcinoid syndrome
and carcinoid heart disease (CHD). A multi-disciplinary
decision was taken to proceed to valvular surgery with PFO
closure. During induction for the operation, the patient
developed severe hypotension with fulminant circulatory
collapse and died before surgery could be undertaken.
Discussion
Carcinoid syndrome is a clinical manifestation of a well-
differentiated neuroendocrine tumour (NET). The NET
arises from enterochromaffin cells, located in either the
gastrointestinal tract or the lungs, which are responsible
for the release of vasoactive substances such as serotonin.
Carcinoid syndrome usually occurs in patients with
metastatic lesions to the liver, which results in failure
of hepatic inactivation of the vasoactive substances
or their release directly into the systemic circulation.
The characteristic symptoms are diarrhoea, cutaneous
flushing and bronchoconstriction. Carcinoid tumours are
rare, with an estimated incidence of 1–2 per 100,000 in
the United States of America (1, 2).
Carcinoid syndrome can present a diagnostic
challenge to physicians, due to its indolent presentation,
in association with an unusual constellation of symptoms.
The typical time from onset of symptoms to diagnosis is
24–28 months, but is sometimes as long as 5 years (3).
Diagnosis can be reached using a combination of 24-h
HIAA urinary excretion levels, blood tests for 5-HIAA
and chromogranin and imaging modalities. Imaging
techniques used include CT, MRI, OctreoScan scintigraphy
and positron emission tomography integrated with CT
(PET CT). Biopsies allow tissue diagnosis and confirm the
degree of differentiation of the tumour.
CHD is a known complication of carcinoid syndrome. It is
estimated to occur in over 50% of patients with this condition
(4). The pathophysiology is via a paraneoplastic effect of the
high levels of secreted vasoactive substances on the right
heart, without inactivation of these substances by the liver.
This results in fibrous plaque deposition and endocardial
thickening, which can cause retraction, distortion and
fixation of the right-sided heart valves. This results in valvular
regurgitation, stenosis or both. The vasoactive substances are
degraded within the lungs, therefore, relatively protecting
the left heart from the disease (3, 4).
Patients with CHD typically present with signs of
severe tricuspid regurgitation and right heart failure in
association with classical systemic carcinoid syndrome
symptoms. Valvular surgery is the only definitive
treatment of CHD, with prosthetic valvular replacement
usually preferred when patients are considered suitable
operative candidates (3). Other strategies address symptom
control though treatment of right ventricular failure with
diuretics. Somatostatin analogues can relieve carcinoid
symptoms and slow tumour growth (5).
In the case described, the patient had symptoms of
carcinoid syndrome with echocardiographic evidence
of CHD. However, in spite of severe tricuspid valvular
disease, there were no clinical features of right heart
failure due to the unique haemodynamic adaptation
created by the shunt. The right heart was effectively
offloading through the PFO, causing a right-to-left shunt.
Although this had prevented fulminant features of right
heart failure, this came at the expense of an induced state
of profound hypoxia created by the shunt. As such, this is
a unique presentation of this condition as it came to light
from symptoms relating to the hypoxia, rather than those
typically described in this condition.
PFO, in its own right, is a common phenomenon,
present in 25% of the population. It is usually benign and
not associated with a significant shunt as left atrial pressure
is higher than right atrial pressure in the physiologically
normal heart (6). In the case described, the torrential
tricuspid regurgitation caused by CHD resulted in raised
right atrial pressure; this in turn caused the continuous right-
to-left shunt across the PFO creating a haemodynamically
significant lesion. A single small study has identified a
higher incidence of significant PFO in patients with CHD
compared with age-matched controls and suggests that in
some cases there may be a role for percutaneous closure
of haemodynamically significant lesions (7). Symptoms of
platypnea–orthodeoxia syndrome have been reported in
patients with a PFO and an additional predisposing feature,
which results in significant shunting of blood from the right
atrium to left atrium (8). Although physiologically feasible
in the case described, the symptoms of this syndrome were
not specifically described by the patient.
D Hammersley, A Shamsi
etal.
An unusual cause of hypoxia K11
5:1
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International License.
https://doi.org/10.1530/ERP-17-0055
www.echorespract.com © 2018 The authors
Published by Bioscientica Ltd
The presence of a PFO in a patient with carcinoid
syndrome also creates a conduit for passage of the
vasoactive substances released in carcinoid syndrome
from the right heart to the left heart. This can, in theory,
result in the involvement of left-sided heart valves in
addition to the right-sided heart valves and has been
described elsewhere in the literature (9).
Declaration of interest
The authors declare that there is no conict of interest that could be
perceived as prejudicing the impartiality of this case report.
Funding
This research did not receive any specic grant from any funding agency in
the public, commercial or not-for-prot sector.
Patient consent
The patient is deceased. Written consent for publication of the submitted
article and accompanying images and videos has been given from the
patient’s next-of-kin.
Author contribution statement
D H and A S drafted the manuscript and contributed equally as rst author.
M M Z contributed to the manuscript. P B was involved in the patient’s care
and reviewed the manuscript. L S was involved in the patient’s care and
reviewed the manuscript.
References
1 MøllerJE, ConnollyHM, RubinJ, SewardJB, ModestoK &
PellikkaPA. Factors associated with progression of carcinoid heart
disease. New England Journal of Medicine 2003 348 1005–1015.
(https://doi.org/10.1056/nejmoa021451)
2 BertinN, FavrettoS, PelizzoF, MosL, PertoldiF & VrizO. Carcinoid
heart disease: starting from heart failure. Journal of Investigative
Medicine High Impact Case Reports 2017 5 2324709617713511.
(https://doi.org/10.1177/2324709617713511)
3 FoxDJ & KhattarRS. Carcinoid heart disease: presentation,
diagnosis, and management. Heart 2004 90 1224–1228. (https://doi.
org/10.1136/hrt.2004.040329)
4 ConnollyHM & PellikkaPA. Carcinoid heart disease. Current
Cardiology Reports 2006 8 96–101. (https://doi.org/10.1007/s11886-
006-0019-9)
5 Van der LelyAJ & de HerderWW. Carcinoid syndrome: diagnosis
and medical management. Arquivos Brasileiros de Endocrinologia
and Metabologia 2005 49 850–860. (https://doi.org/10.1590/s0004-
27302005000500028)
6 HagenPT, ScholzDG & EdwardsWD. Incidence and size of patent
foramen ovale during the first 10 decades of life: an autopsy study of
965 normal hearts. Mayo Clinic Proceedings 1984 59 17–20. (https://
doi.org/10.1016/S0025-6196(12)60336-X)
7 MansencalN, MitryE, PillièreR, LepèreC, GérardinB, PetitJ,
GandjbakhchI, RougierP & DubourgO. Prevalence of patent
foramen ovale and usefulness of percutaneous closure device in
carcinoid heart disease. American Journal of Cardiology 2008 101
1035–1038. (https://doi.org/10.1016/j.amjcard.2007.11.056)
8 AlkhouliM, GagelA, MathurM & O’MurchuB. Platypnea-
orthodeoxia syndrome: an unusual complication of partial liver
resection. Internal Medicine 2015 54 1067–1069. (https://doi.
org/10.2169/internalmedicine.54.3617)
9 ConnollyHM, SchaffHV, MullanyCJ, RubinJ, AbelMD &
PellikkaPA. Surgical management of left-sided carcinoid heart
disease. Circulation 2001104 I36–I40. (https://doi.org/10.1161/
hc37t1.094898)
Received in nal form 8 November 2017
Accepted 8 November 2017
... Progressive dyspnea in carcinoid disease seen in the setting of a PFO is much more often related to the development of left-sided valve disease which is caused by right-to-left shunting due to a rise in right trial pressure in right sided heart failure. Here, an interventional closure of PFO is associated with clinical improvement (5,(18)(19)(20). As our patient also demonstrated right-sided and subsequently, also left-sided valve disease, an occluder device was used to prevent further right-to-left shunting through the PFO. ...
Article
Full-text available
Background Neuroendocrine tumors (NETs) can affect the cardiopulmonary system causing carcinoid heart disease and valve destruction. Persistent foramen ovale (PFO) occlusion is indicated in patients with carcinoid heart disease and shunt-related left-heart valve involvement. Case Summary We report the case of a 54-year-old female patient with metastatic NET originating from the small bowel. The patient was on medication with octreotide and telotristat. One year after diagnosis, cardiac involvement of carcinoid developed with regurgitation of right-sided and, due to PFO, left-sided heart valves. Closure of PFO was performed (Occlutech 16/18 mm). One year later she presented with recurrent severe dyspnoea. The PFO-occluder was in situ without residual shunt. Valvular heart disease, including left-sided disease, and metastatic spread of NET were stable. Blood gas analysis revealed arterial hypoxemia (pO2 = 44 mmHg/5.87 kPa), which was related to extensive intrapulmonary shunting (31% shunt fraction) confirmed using contrast-enhanced echocardiography. The patient was prescribed long-term oxygen supplementation as symptomatic therapy and anti-tumoral therapy was intensified with selective internal radiotherapy of the liver metastases in order to improve biochemical control of the carcinoid syndrome. Discussion An echocardiographic assessment of the presence of a PFO is recommended in patients with NET as PFO closure minimizes the risk of left-sided carcinoid valve disease. Deterioration of symptomatic status in metastasized NET might also be due to a hepatopulmonary-like physiology with intrapulmonary shunting and arterial desaturation thought to be caused by vasoactive substances secreted by the tumor. This is a rare case describing the development of this syndrome after PFO closure.
... Definitive therapy is achieved through surgical valve replacement; however, identifying the proper patients or the ideal timing has been shown to be challenging. [17][18][19] It is advised to take a multidisciplinary approach to these patients involving cardiologists, cardiothoracic surgeons, oncologists, and endocrinologists. Carcinoid heart disease imparts significant morbidity and mortality, and surgical intervention should be considered when symptomatic disease exists. ...
Article
Full-text available
Background Carcinoid syndrome is a rare disease caused by malignant neuroendocrine neoplasms. When vasoactive substances enter the systemic circulation, the triad of cutaneous flushing, bronchospasm, and diarrhoea often characterize carcinoid syndrome. Rarely, carcinoid syndrome can progress to involve the cardiac system, a condition known as carcinoid heart disease, often affecting right-sided valvular structures. Case summary Here, we present a case of malignant carcinoid syndrome with associated carcinoid heart disease in a 63-year-old female. The diagnosis of her dual regurgitant and stenotic valvular disease is detailed, with accompanying two- and three-dimensional echocardiographic images demonstrating the patient’s complex tricuspid dysfunction. Discussion Carcinoid heart disease encompasses a rare but important subset of valvular dysfunction caused by circulating vasoactive substances. Diagnosis utilizing serum studies, computed tomography scans, and echocardiography can help expedite the diagnosis and treatment of such rare conditions, and assist in the avoidance of complications. Despite its relatively well-recognized clinical presentation, carcinoid syndrome and its associated heart disease still remains a challenging condition to manage and treat, often requiring the input of several subspecialties to treat the condition appropriately.
Article
The patent foramen ovale (PFO) is a flap or tunnel-like communication in the atrial septum present in 20% to 34% of the adult population. In most cases, it is a benign finding and poses no health risk. However, some PFOs may provide a conduit for bloodborne materials, such as thrombi, vasoactive substances, or air to pass into the systemic circulation causing a paradoxical embolus. PFOs have been linked with several clinical disease states including cryptogenic stroke, migraine headache, platypnea-orthodeoxia, and decompression illness. Percutaneous PFO closure provides a practical solution to the problem of PFO in carefully selected populations. Recent randomized control trials have demonstrated that PFO closure in patients with cryptogenic stroke is associated with reduced rates of recurrent stroke compared with medical therapy. This translated into a dramatic increase in the number of PFO closure procedures worldwide, primarily for the indication of cryptogenic stroke, with high procedural success and low complication rates. However, there are no randomized clinical trials available to support PFO closure in other clinical conditions. This article reviews potential indications, existing data, and management approaches for PFO closure in disorders other than cryptogenic stroke.
Article
Full-text available
Carcinoid syndrome is the constellation of symptoms mediated by humoral factors produced by some carcinoid tumors. It consists primarily of vasomotor symptoms, gastrointestinal hypermotility, hypotension, and bronchospasm, due to the production and release of vasoactive substances. Carcinoid heart disease occurs in more than 50% of patients with carcinoid syndrome; in some cases, it represents the initial manifestation of the disease. We report the case of a 75-year-old woman with a metastatic neuroendocrine tumor admitted to the emergency room for fatigue and heart failure. Transthoracic echocardiography showed severe tricuspid and pulmonic regurgitation suggesting carcinoid heart disease. A hypervascular retroperitoneal mass was found on abdominal computed tomography, which seemed to arise from the mesenteric artery, anteriorly to the abdominal aorta. Unfortunately, our patient was neither a candidate for mass resection nor for cardiac surgery due to advanced metastatic disease and poor clinical condition. Additionally, we performed a systematic literature review of carcinoid heart disease focusing on typical echocardiographic findings.
Article
Full-text available
Platypnea-orthodeoxia syndrome (POS) is a rare syndrome of severe hypoxemia upon assuming an upright position. It is classically described as shunting from the right atrium to the left atrium usually via a patent foramen ovale (PFO). Alterations in the intrathoracic anatomy after liver resection and regeneration may trigger this condition in patients with clinically silent PFO -a previously unreported cause of POS.
Article
Full-text available
Tricuspid and pulmonary valve regurgitation usually occurs as a secondary phenomenon caused by dilatation of the valve ring secondary to right ventricular failure or pulmonary hypertension, respectively. Primary diseases of the tricuspid or pulmonary valves are uncommon, but the more likely causes might include congenital abnormalities, rheumatic heart disease, or infective endocarditis. Carcinoid heart disease is a rare, but interesting and important cause of intrinsic tricuspid and pulmonary valve disease leading to significant morbidity and mortality caused by right heart failure. When treated medically, and in appropriate cases surgically, significant benefits in overall quality of life and long term survival can be achieved. We review the current literature regarding the pathophysiological basis of the disease, the cardiovascular complications, and the currently available treatment strategies. Carcinoid tumours are rare neuroendocrine malignancies arising from neural crest amine precursor uptake decarboxylation cells. Approximately 90% of all carcinoid tumours are located in the gastrointestinal system of which the most common sites are the appendix and terminal ileum. Other less common sites include the bronchus and gonads. The most malignant of the carcinoid tumours tend to arise from the ileum and must be invasive or metastasise to produce the carcinoid syndrome which is characterised by facial flushing, intractable secretory diarrhoea, and bronchoconstriction. The incidence of carcinoid tumours is approximately 1 in 75 000 of the population1 of whom about 50% develop carcinoid syndrome. Once the carcinoid syndrome has developed, approximately 50% of these patients develop carcinoid heart disease which typically causes abnormalities of the right side of the heart. Usually, only carcinoid tumours that invade the liver result in pathological changes to the heart. The cardiac manifestations are caused by the paraneoplastic effects of vasoactive substances such as 5-hydroxytryptamine (5-HT or serotonin), histamine, tachykinins, and prostaglandins released by the malignant cells rather than any …
Article
Full-text available
Gastro-intestinal carcinoids are slow growing tumors arising from enterochromaffin or Kulchitsky cells. Their clinical presentation depends on what combination of bioactive substances is secreted. Midgut carcinoid can present with the carcinoid syndrome in the presence of liver metastases. Its most typical clinical manifestations include cutaneous flushing and diarrhea. A nonspecific biochemical tumor marker for carcinoid tumors is serum chromogranin A and a specific marker for the carcinoid syndrome is the increased urinary excretion of 5-hydroxy indole acetic acid (5-HIAA). Localizing studies in carcinoid tumors/syndrome are: transabdominal ultrasonography (US), endoscopy, endoscopic US, videocapsule endoscopy, computerized tomography, magnetic resonance imaging, selective abdominal angiography, 111In-pentetreotide scintigraphy (and intraoperative radionuclide probe), 123I (131I)-metaiodobenzylguanidine (MIBG) scintigraphy, bone scintigraphy and 11C-5-HT positron emission tomography (PET). Therapies for carcinoid tumors/syndrome are: surgery, somatostatin analogs, interferon-alpha, radiotherapy, liver dearterialization, liver (chemo, or radio)-embolization, alcohol sclerotherapy of liver metastases, radiofrequency ablation of liver metastases, cryosurgery of liver metastases, occasionally liver transplantation, radiotherapy-coupled somatostatin analogs, 131I-MIBG and occasionally chemotherapy.
Article
The incidence and size of the patent foramen ovale were studied in 965 autopsy specimens of human hearts, which were from subjects who were evenly distributed by sex and age. Neither incidence nor size of the defect was significantly different between male and female subjects. The overall incidence was 27.3%, but it progressively declined with increasing age from 34.3% during the first three decades of life to 25.4% during the 4th through 8th decades and to 20.2% during the 9th and 10th decades. Among the 263 specimens that exhibited patency in our study, the foramen ovale ranged from 1 to 19 mm in maximal potential diameter (mean, 4.9 mm). In 98% of these cases, the foramen ovale was 1 to 10 mm in diameter. The size tended to increase with increasing age, from a mean of 3.4 mm in the first decade to 5.8 mm in the 10th decade of life.
Article
Carcinoid involvement of left-sided heart valves has been reported in patients with a patent foramen ovale, carcinoid tumor of the lung, and active carcinoid syndrome with high levels of serotonin. The present study details the clinical features and surgical management of patients with carcinoid heart disease affecting both left- and right-sided valves. Eleven patients (7 men, 4 women) with symptomatic carcinoid heart disease underwent surgery for left- and right-sided valve disease between 1989 and 1999. Mean age was 57+/-9 years, and median preoperative NYHA class was 3. All patients had metastatic carcinoid tumors and were on somatostatin analog. Of 11 patients, 5 (45%) had a patent foramen ovale; 1 of these also had a primary lung carcinoid tumor. Surgery included tricuspid valve replacement in all patients, pulmonary valve replacement in 3 and valvectomy in 7, mitral valve replacement in 6 and repair in 1, aortic valve replacement in 4 and repair in 2, CABG in 2, and patent foramen ovale closure in 5. One myocardial metastatic carcinoid tumor was removed. There were 2 perioperative deaths. At a mean follow-up of 41 months, 4 additional patients were dead. All but 1 surgical survivor initially improved >/=1 functional class. No patient required reoperation. Carcinoid heart disease may affect left- and right-sided valves and occurred without intracardiac shunting in 55% of this surgical series. Despite metastatic disease that limits longevity, operative survivors had improvement in functional capacity. Cardiac surgery should be considered for select patients with carcinoid heart disease affecting left- and right-sided valves.
Article
By releasing vasoactive substances into the circulation, carcinoid tumors can cause right-sided valvular heart disease. Factors associated with the progression of carcinoid heart disease are poorly understood. We conducted a retrospective study to identify such factors. Our sample included 71 patients with the carcinoid syndrome who underwent serial echocardiographic studies performed more than one year apart and 32 patients referred directly for surgical intervention after an initial echocardiographic evaluation. A score for carcinoid heart disease was determined on the basis of an assessment of valvular anatomy and function and the function of the right ventricle. An increase of more than 25 percent in the score between studies was considered suggestive of disease progression. Tumor progression was assessed on the basis of abdominal computed tomographic scans and changes in the level of urinary 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin. Of the patients with serial echocardiographic studies, 25 (35 percent) had an increase of more than 25 percent in the cardiac score. As compared with patients whose score changed by 25 percent or less, these patients had higher urinary peak 5-HIAA levels (median, 265 mg per 24 hours [interquartile range, 209 to 593] vs. 189 mg per 24 hours [interquartile range, 75 to 286]; P=0.004) and were more likely to have biochemical progression (10 of 25 patients vs. 9 of 46, P=0.05) and to have received chemotherapy (13 of 25 vs. 10 of 46, P=0.009). Logistic-regression analysis showed that a higher peak urinary 5-HIAA level and previous chemotherapy were predictors of an increase in the cardiac score that exceeded 25 percent (odds ratio for each increase in 5-HIAA of 25 mg per 24 hours, 1.08 [95 percent confidence interval, 1.03 to 1.13]; P=0.009); odds ratio associated with chemotherapy, 3.65 [95 percent confidence interval, 1.74 to 7.48]; P=0.001). Serotonin is related to the progression of carcinoid heart disease, and the risk of progressive heart disease is higher in patients who receive chemotherapy than in those who do not.
Article
In patients with carcinoid heart disease, a multidisciplinary approach to patient care is required because treatment of the systemic disease and management of cardiac involvement must be considered at the same time. Somatostatin analogue use is a therapeutic cornerstone, effective in symptomatic control of the endocrine syndrome. Chemotherapy is of limited efficacy in patients with carcinoid tumors. Hepatic resection of metastases is the preferred treatment option and has been shown to result in improved outcome. It should be considered if at least 90% of the metastases in the liver are removable. Hepatic artery embolization is usually applied if a patient is not eligible for surgical debulking. Development and progression of carcinoid heart disease complicate the carcinoid syndrome and contribute to poor prognosis. In patients with severe cardiac involvement and well-controlled systemic disease, valve replacement surgery is an effective treatment modality that can relieve intractable symptoms and contribute to improved outcome.
Article
The aim of this study was to assess (1) the incidence of patent foramen ovale (PFO) in carcinoid syndrome (CS) and (2) the feasibility of percutaneous closure procedure in selected patients with CS. One hundred eight patients were prospectively studied: 54 with CS and an age- and gender-matched control group. All patients underwent conventional and contrast echocardiography. Patients with clinical signs of dyspnea (New York Heart Association class > or =III), cyanosis, carcinoid heart disease (CHD), and severe PFO were referred for the percutaneous closure of PFO. The prevalence of PFO was 41% in patients with CS and 22% in the control group (p = 0.03) and was significantly higher in patients with CHD (59%, p = 0.009). Four patients (14% of those with CHD) were referred for the percutaneous closure of PFO, and 3 patients ultimately underwent PFO closure (using Amplatzer septal occluders). At 6-month follow-up, New York Heart Association class was improved in all patients, as well as arterial blood gas results (p = 0.04) and 6-minute walking distance (p = 0.03), but all patients presented residual right-to-left shunts. In conclusion, this prospective study demonstrates that in patients with CHD, the prevalence of PFO is high and that percutaneous closure of PFO is feasible, with a reduction in symptoms but with residual shunting.
eCollection 3. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart
  • N Bertin
  • S Favretto
  • F Pelizzo
  • L Mos
  • F Pertoldi
  • O Vriz
Bertin N, Favretto S, Pelizzo F, Mos L, Pertoldi F, Vriz O. Carcinoid Heart Disease: Starting From Heart Failure. Journal of Investigative Medicine High Impact Case Reports. 2017 5 eCollection 3. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004 90 1224-1228.